ClinicalTrials.gg

Program

gocatamig

Its studies are mostly in Small Cell Lung Carcinoma, led by Merck.

Furthest: phase 3, since Oct 26, 20264 company-led studies, 4 open or runningNext primary completion: Jan 28, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck44 open or runningphase 3since Oct 26, 2026Jul 6, 2020Jan 28, 2028phase 2 · NCT04471727
  • Named in Merck’s own pipeline as gocatamig (MK-6070), phase 2, as of Nov 2, 2026 (source).

Also a collaborator on its studies: Daiichi Sankyo.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2020First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT04471727 · 232 enrolled · United States
  2. Jan 13, 2025Phase 2 study in Small Cell Lung CarcinomaNCT06780137 · 327 planned · United States, Argentina, Australia and more
  3. Nov 10, 2025Phase 2 study in Small Cell Lung Cancer Extensive StageNCT07227597 · 170 planned · United States, Argentina, Chile and more
  4. Oct 26, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedNCT07908537 · 564 planned

Ahead

  1. Jan 28, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT04471727
  2. Feb 15, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06780137
  3. Nov 29, 2030Primary completion: phase 2 study in Small Cell Lung Cancer Extensive StageNCT07227597
  4. Dec 8, 2031Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07908537

TargetBeta

“A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) containing three humanized antibody derived binding domains: a N-terminal single chain Fv (scFv) that binds to the epsilon domain of CD3 antigen (CD3e) of the T cell receptor (TCR), a middle single dom…”NCIt, read by Claude
“A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) containing three humanized antibody derived binding domains: a N-terminal single chain Fv (scFv) that binds to the epsilon domain of CD3 antigen (CD3e) of the T cell receptor (TCR), a middle single domain”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
SHR-7787Jiangsu HengRui Medicinephase 21
clesitamigHoffmann-La Rochephase 12
HLX3901Fosun Pharmaphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07908537Small Cell Lung Carcinoma3Not yet recruitingDec 8, 2031564
NCT07227597Small Cell Lung Cancer Extensive Stage · United States, Argentina, Chile and more2RecruitingNov 29, 2030170
NCT06780137Small Cell Lung Carcinoma · United States, Argentina, Australia and more2RecruitingFeb 15, 2029327
NCT04471727Small Cell Lung Carcinoma · United States2Active, not recruitingJan 28, 2028232

How it is read

Names in the registry

  • “Gocatamig”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.